B244 Emerging Drug Insight and Market Forecast - 2032

B244 Emerging Drug Insight and Market Forecast − 2032

“B244 Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about B244 for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the B244 for atopic dermatitis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the B244 for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the B244 market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

Drug Summary

AOBiome’s B244 is a patented, proprietary, topical formulation incorporating a single strain of beneficial ammonia-oxidizing bacteria (AOB), Nitrosomonas eutropha D23. B244 is designed to repopulate the skin microbiome with AOBs normally found on the body but frequently stripped away by most soaps. Once deployed on the skin, B244 converts ammonia to nitrite, known to have antibacterial properties, and to nitric oxide, a signaling molecule known to regulate inflammation and vasodilation.

In June 2017, the company entered into a Preferred Provider Agreement (PPA) to conduct a Phase IIa clinical trial for B244 for the treatment of pruritus in adults with a history of AD. In addition, the company has collaborated with bioRASI to conduct the Phase IIb trial to treat the patients with AD.

In June 2020, the company initiated a Phase IIb clinical trial in pruritus (itch) associated with AD based on positive clinical trial results related to the investigation of B244 in patients with AD in a Phase IIa clinical trial in adults, as well as a Phase Ib clinical trial in pediatric patients.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the B244 description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.

Elaborated details on B244 regulatory milestones and other development activities have been provided in this report.

The report also highlights the B244 research and development activities in atopic dermatitis across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around B244.

The report contains forecasted sales of for atopic dermatitis till 2032.

Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.

The report also features the SWOT analysis with analyst views for B244 in atopic dermatitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

B244 Analytical Perspective by DelveInsight

In-depth B244 Market Assessment

This report provides a detailed market assessment of B244 for atopic dermatitis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

B244 Clinical Assessment

The report provides the clinical trials information of B244 for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence B244 dominance.

Other emerging products for atopic dermatitis are expected to give tough market competition to B244 and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of B244 in atopic dermatitis.

Our in-depth analysis of the forecasted sales data of B244 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the B244 in atopic dermatitis.

Key Questions

What is the product type, route of administration and mechanism of action of B244?

What is the clinical trial status of the study related to B244 in atopic dermatitis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the B244 development?

What are the key designations that have been granted to B244 for atopic dermatitis?

What is the forecasted market scenario of B244 for atopic dermatitis?

What are the forecasted sales of B244 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to B244 for atopic dermatitis?

Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?